New molecular targeted therapies for advanced non-small-cell lung cancer

Journal of Thoracic Disease

Volumn 3, Issue 1, 2011, Pages 30-56

  Méndez, Míriam ^a   Custodio, Ana ^a   Provencio, Mariano ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Advanced non small cell lung cancer; Angiogenesis; EML4 ALK fusion oncogene; Epidermal growth factor receptor (EGFR); Histone deacetylase Inhibition; Immunotherapy; Insulin like growth factor 1 receptor (IGF 1R); Proteasome inhibition; Targeted therapies

Indexed keywords

EID: 80052437059     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2010.12.03     Document Type: Review

References (134)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA. Cancer J. Clin 2008;58:71-96.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
4. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor in lung cancer. N Engl J Med 2009;361:958-67.
5. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397-405.
6. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
7. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5.
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7.
9. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-70.
10. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible par-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32.
11. Janne PA, Schellens JH, Engelman JA, Eckhardt SG, Millham R, Denis LJ, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC [abstract]. J Clin Oncol 2008;s26:8027.
12. Park K, Heo DS, Cho B, Kim D, Ahn M, Lee S, et al. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II trial [abstract]. J Clin Oncol 2010;s28:7599.
13. Campbell A, Reckamp KL, Camidge DR, Giaccone G, Gadgeel SM, Khuri FR, et al. PF-00299804 (PF299) patients (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E) [abstract]. J Clin Oncol 2010;s28:7596.
14. Boyer MJ, Blackhall FH, Park K, Barrios CH, Krzakowski MJ, Taylor I, et al. Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced nn-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) [abstract]. J Clin Oncol 2010;s28:LBA7523.
15. Wong KK. HKI-272 in non small cell lung cancer. Clin Cancer Res 2007;13:4593-6.
16. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al.Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83
17. Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, et al. Allele dependent variation in the relative cellular potency of distint EGFR inhibitors. Cancer Biol Ther 2007;6:661-7.
18. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
19. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to geftitinib. Proc Natl Acad Sci USA 2005;102:7665-70.
20. Wakelee HA, Fehling JM, Molina JR, Lensing JL, Funke RP, Miles D, et al. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM) [abstract]. J Clin Oncol 2008;s26:3528.
21. Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, et al. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutation: Results from Phase 2 [abstract]. J Clin Oncol 2008;s26:8053.
22. Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, et al. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial [abstract]. J Clin Oncol 2008;s26:8028.
23. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
24. Yang C, Shih J, Chao T, Tsai C, Yu C, Yang P, et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial [abstract]. J Clin Oncol 2008;s26:8026.
25. Yang C, Hirsh V, Cadranel J, Chen Y, Park K, Kim S, et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report [abstract]. J Clin Oncol 2009;s27:8062.
26. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
27. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9.
28. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results form a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-9.
29. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-15.
30. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. A randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007;25:4270-7.
31. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26.
32. De Boer R, Arrieta O, Gottfried M, Blackhall FH, Raats J, Yang CH, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double blind phase III trial (ZEAL) [abstract]. J Clin Oncol 2009;s27:8010.
33. Lee J, Hirsch V, Park K, Qin S, Blajman CR, Perng R, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR) [abstract]. J Clin Oncol 2010;s28:7525.
34. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST) [abstract]. J Clin Oncol 2009;s27:8009.
35. Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, et al. Phase I and pharmacokinetic study of daily oral AZD 2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2008;26:1871-8.
36. Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009;45:782-8.
37. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized, double blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 Study. J Clin Oncol 2009;28:49-55.
38. Dy GK, Mandrkar SJ, Nelson GD, Ross HJ, Ansari RH, Lyss AP, et al. A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED] as first-line therapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;s28:7603.
39. Toner GC, Mitchell PL, de Boer R, Gibbs P, Hicks R, Scott AM, et al. PET imaging study of SU11248 in patients with advanced malignancies [abstract]. J Clin Oncol 2003;s22:767.
40. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 2008; 26:650-6.
41. Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8.
42. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-6.
43. Novello S, Camps C, Grossi F, Mazieres J, Abrey LE, Vernejoux J, et al. Phase II study of sunitinib in patients with advanced non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results [abstract]. J Clin Oncol 2010;s28:7581.
44. Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis [abstract]. J Clin Oncol 2006;s24:7194.
45. Adjei AA. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group Study [abstract]. J Clin Oncol 2007;s5:7547.
46. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small cell lung cancer [abstract]. J Clin Oncol 2009;27:4274-80.
47. Schiller J, Lee J, Hanna N, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 [abstract]. J Clin Oncol 2008;s26:8014.
48. Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, et al. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 2010;28:844-53.
49. Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis [abstract]. J Clin Oncol 2006;s24:7194.
50. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer. J Clin Oncol 2010;28:1835-42.
51. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52.
52. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel carboplatin in non-small-cell lung cancer: A phase III trial- INTACT 2. J Clin Oncol 2004;22:785-94.
53. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
54. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-31.
55. Gauler TC, Besse B, Meric JB, Gounant V, Fischer B, Overbeck T, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2007;s25:7541.
56. Blumenschein GJ, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006;s24:7119.
57. Blumenschein GJ, Kabbinavar FF, Menon H, Mok T, Stephenson J, Beck JT, et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;s28:7528.
58. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7.
59. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small cell lung cancer. J Clin Oncol 2010;28:3131-7.
60. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-9.
61. Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Staab A, et al. A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. Proceedings of the 2009 World Conference on Lung Cancer; 2008 Oct 1-5; Dresden, Germany.
62. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
63. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999;91:151-6.
64. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small-cell lung cancer. Clin Cancer Res 2002;8:3669-75.
65. Pollak M, Eisenberg P, Karp D, Cohen R, Kreisman H, Adjei A, et al. Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors [abstract]. American Association for Cancer Research Annual Meeting 2007:LB-343.
66. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-22
67. Han JY, Choi BG, Choi JY, Lee SY, Ju SY. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small-cell lung cancer. Lung Cancer 2006;54:227-34.
68. Jassem C, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;s28:7500.
69. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:s5549-55.
70. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol 2008:s26:3519.
71. Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule [abstract]. J Clin Oncol 2008;s26:3520.
72. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009;63:169-79.
73. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
74. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplifications occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7.
75. Schiller JH, Akerley WL, Brugger W, Ferrari D, Garmey EG, Gerber DE, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2010;s28:LBA7502.
76. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-8.
77. Crul M, de Klerk GJ, Beijnen JH, Schellens JH. Ras biochemistry and farnesyl tranferase inhibitors: a literature survey. Anticancer Drugs 2001;12:163-84.
78. Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20:2726-35.
79. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001;19:1167-75.
80. Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2003;21:1760-6.
81. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung cancer. Cancer 2005;104:561-9.
82. Coudert B, Anthoney A, Fiedler W, Droz JP, Dieras V, Borner M, et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment (EORTC) Early Clinical Studies Group report. Eur J Cancer 2001;37:2194-8.
83. Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 2007;63:172-82.
84. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, et al. Frequent activation of AKT in non-small-cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-9.
85. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68:6913-21.
86. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-91.
87. Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 2007;63:172-82.
88. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
89. Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2006;65:3226-35.
90. Sun SY, FU H Khuri FR. Targeting mTOR signaling for lung cancer therapy. J Thorac Oncol 2006;1:109-11.
91. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2000;12:5755-63.
92. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47.
93. Pandya KJ, Levy DE, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report [abstract]. J Clin Oncol 2005;s23:7005.
94. Molina JR, Mandrekar SJ, Rowland K, Reuter NF, Jett JR, Marks R, et al. A phase II NCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC: D7-O7. J Thorac Oncol 2007;2:s413
95. Pacey S, Rea D, Steven N, Brock C, Knowlton N, Shand N, et al. Results of a phase I clinical trial investigating a combination of the oral mTOR inhibitor everolimus (E, RAD001) and gemcitabine (GEM) in patients (pts) with advanced cancer [abstract]. J Clin Oncol 2004;s22:3120.
96. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-81.
97. Nogova L, Zander T, Gross SH, Pellas T, Hayes W, Thomas R, et al. Mammalian target of rapamycin (mTOR) inhibition by RAD001 in patients (pts) with recurrent non-small cell lung cancer (NSCLC): Use of 18F fluorodeoxyglucose positron-emission tomography (FDG-PET) in evaluation of the pharmacodynamic effect. J Thorac Oncol 2007;2:s583.
98. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/- mice. Proc Natl Acad Sci USA 2001;98:10320-5.
99. Baselga J, Van Dam PA, Greil R, Gardner H, Bandaru R, Molloy B, et al. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER + breast cancer [abstract]. J Clin Oncol 2008;s26:530.
100. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-23.
101. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103:1475-9.
102. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
103. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:10031-3.
104. Murakami S, Yokose T, Saito H, Sakuma Y, Matsukuma S, Hasegawa C, et al. Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. Lung Cancer 2010;69:361-4.
105. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-80.
106. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
107. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76.
108. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
109. Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, et al. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 2009;8:1940-51.
110. Davies AM, Lara PN Jr, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007;13:s4647-51.
111. Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006;1:996-1001.
112. Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 2010;68:89-93.
113. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-33.
114. Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;68:420-6.
115. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
116. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1002-9.
117. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008;68:29-36.
118. Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010;11:36-44.
119. Hobdy E, Murren J. AN-9 (Titan). Curr Opin Investig Drugs 2004;5:628-34.
120. Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res 2005;15:39-48.
121. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 2009;4:522-6.
122. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007;13:3605-10.
123. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62.
124. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010;126:743-55.
125. Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 2010 Aug 5. [Epub ahead of print].
126. Nagji AS, Cho SH, Liu Y, Lee JK, Jones DR. Multi-gene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 2010 Aug 16. [Epub ahead of print].
127. Lee SM, Lee JY, Choi JE, Lee SY, Park JY, Kim DS. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features. Cancer Genet Cytogenet 2010;197:39-45.
128. Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 2009;10:20-7.
129. Mauro LV, Dalurzo M, Smith D, Lastiri J, Vasallo B, Joffei EB, et al. Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma. Medicina (B Aires) 2008;68:205-12.
130. Tyagi P. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: Results from the SPIRIT I and II trials. Clin Lung Cancer 2005;7:17-9.
131. Bogos K, Renyi-Vamos F, Kovacs G, Tovari J, Dome B. Role of retinoic receptors in lung carcinogenesis. J Exp Clin Cancer Res 2008;27:18.
132. Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL, Martínez-Barrera L, et al. Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3463-71.
133. Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 2009 Feb 19. [Epub ahead of print].
134. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5774-8.